TABLE 1.

Patient Characteristics

Characteristics	Male		Female
	No.	%	No.	%	p
All patients	385	0.6	68,065	99.4
Age at diagnosis, y
<50	124	32.2	27,099	39.8	<.0001
50–64	142	36.9	29,158	42.8
>64	119	30.9	11,808	17.3
Race
White	299	77.7	52,110	76.6	.235
Black	69	17.9	11,421	16.8
Other	15	3.9	3995	5.9
Unknowna	2	0.5	539	.8
Median income
<$40,227	72	18.7	11,434	16.8	.409
$40,227–$50,353	84	21.8	13,635	20.0
$50,354–$63,332	90	23.4	15,707	23.1
≥$63,333	135	35.1	26,475	38.9
Unknowna	4	1.0	814	1.2
Charlson‐Deyo score
0	325	84.4	59,463	87.4	.038
1	44	11.4	7050	10.4
2	10	2.6	1155	1.7
≥3	6	1.6	397	.6
Histology
Ductal	330	85.7	56,835	83.5	.281
Lobular	13	3.4	3619	5.3
Mixed ductal and lobular	11	2.9	2307	3.4
Mixed ductal and other	12	3.1	1490	2.2
Carcinoma	19	4.9	3814	5.6
Grade
I	29	7.5	3410	5.0	<.0001
II	159	41.3	21,728	31.9
III/IV	167	43.4	38,075	55.9
Unknowna	30	7.8	4852	7.1
Clinical stage
I	33	8.6	7450	10.9	.004
II	207	53.8	40,145	59.0
III	145	37.7	20,470	30.1
Tumor subtype
HR+/HER2–	206	53.5	25,326	37.2	<.0001
HR+/HER2+	112	29.1	15,539	22.8
HR–/HER2+	25	6.5	8198	12.0
Triple negative	42	10.9	19,002	27.9
Surgery
Mastectomy	312	81.0	43,451	63.8	<0.0001
Partial mastectomy	73	19.0	24,593	36.1
Unknown	0	0.0	21	.0%

Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor.

^a Unknown patients are excluded from the comparative analysis.